Indivior (GB:INDV) has released an update.
Indivior PLC has reported a strong performance in Q3 2024, with a 13% increase in net revenue to $307 million, driven largely by a 14% rise in SUBLOCADE’s revenue. The company is actively pursuing cost-saving measures to boost SUBLOCADE growth and address legacy litigation issues, aiming for a significant reduction in operating expenses by 2025. Indivior’s strategic initiatives and settlement agreements indicate a focus on maintaining its leadership in the opioid use disorder treatment market.
For further insights into GB:INDV stock, check out TipRanks’ Stock Analysis page.
